Figure 2.

NuRD Restricts Expression Levels of Actively Transcribed Genes

(A) Expression of indicated genes in Mbd3^−/− ESCs grown in 2i/LIF relative to wild-type cells grown in the same conditions.

(B) ChIP was performed using anti-Mi2β or a mouse IgG control antibody in wild-type ESCs grown in serum and LIF (SL) or in 2i/LIF conditions and probed with primers located at the transcription start sites for the indicated genes.

(C) Expression of indicated genes in wild-type (WT) or Mbd3^−/− ESCs expressing MER-Mbd3b-MER (M3bM) prior to tamoxifen treatment (0 hr) and after 20 or 38 hr of tamoxifen treatment, relative to the expression levels in wild-type ESCs.

(D) MER-Mbd3b-MER goes to NuRD target genes after tamoxifen addition. ChIP was performed using anti-ER or a mouse IgG control antibody in Mbd3^−/− ESCs expressing MER-Mbd3b-MER either in the absence of tamoxifen (0 hr) or after 20 hr of tamoxifen treatment (20 hr), which were then probed with primers located at the transcription start sites for the indicated genes. “GFR” refers to the chromosome 19 gene free region.

^∗p < 0.05, ^∗∗p < 0.005. Error bars represent standard error of the mean (SEM).